Cipla Limited had to tackle some pre-results drama, even as the company reported a strong showing for the third quarter of fiscal 2024, while management commentary on the glucagon‐like peptide 1 (GLP-1) receptor agonist segment signaled huge potential opportunities in store.
Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal
Executive vice chair Samina Hamied moves to non-exec role
Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen.
More from Business
More from Scrip
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.